Overview

A Study to Evaluate Sintilimab Plus Lenvatinib as Adjuvant Therapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis (PVTT) After Surgical Resection

Status:
Not yet recruiting

Trial end date:
2026-11-01

Target enrollment:

Participant gender:

Summary

To compare the impact on recurrence risk of adjuvant Sintilimab (a recombinant fully human anti-PD-1 monoclonal antibody) plus Lenvatinib for patients with hepatocellular carcinoma and portal vein tumor thrombus (PVTT ) after hepatectomy.

Phase:

Phase 3

Details

Lead Sponsor:

Tongji Hospital

Treatments:

Lenvatinib